Spotlight Asset Group’s Checkpoint Therapeutics CKPT Stock Holding History

Spotlight Asset Group’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-661,597	Closed	-$622K	–	248
2023 Q1	$622K	Buy	+661,597	New	+$3.32M	0.62%	27
2022 Q3	$622K	Buy	+66,160	New	+$788K	0.62%	27
2021 Q3	$2.18M	Hold	66,160	–	–	1.09%	22
2021 Q2	$1.95M	Buy	66,160 +1,000	+2%	+$27.7K	0.75%	28
2021 Q1	$2.05M	Buy	65,160 +57,160	+715%	+$1.92M	0.77%	28
2020 Q4	$212K	Hold	8,000	–	–	0.08%	123
2020 Q3	$214K	Hold	8,000	–	–	0.08%	125
2020 Q2	$158K	Hold	8,000	–	–	0.07%	132
2020 Q1	$121K	Hold	8,000	–	–	0.06%	107
2019 Q4	$110K	Buy	+8,000	New	+$134K	0.05%	122

Other funds holding CKPT

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Spotlight Asset Group's CKPT Position: Q2 2023 in Review

Spotlight Asset Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2023, closing a stake of 661,597 shares — an estimated $622K sold.

Spotlight Asset Group first reported a position in CKPT in Q4 2019 and held it in 10 quarters. The position peaked at $2.18M in Q3 2021. 34 funds tracked by Wall St. Rank hold CKPT as of Q2 2023.

Spotlight Asset Group reported no remaining Checkpoint Therapeutics position as of Q2 2023 after selling out during the quarter.
Spotlight Asset Group sold 661,597 Checkpoint Therapeutics shares in Q2 2023, an estimated $622K.
Spotlight Asset Group first reported a position in Checkpoint Therapeutics in Q4 2019 and held it in 10 quarters.
Spotlight Asset Group's Checkpoint Therapeutics position peaked at $2.18M in Q3 2021.
34 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2023.

Based on Spotlight Asset Group's 13F filing for Q2 2023, filed 9 Aug 2023.